<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02149121</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P10 3.2</org_study_id>
    <secondary_id>2013-004555-21</secondary_id>
    <nct_id>NCT02149121</nct_id>
  </id_info>
  <brief_title>PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis</brief_title>
  <acronym>rituximab</acronym>
  <official_title>A Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety Between CT-P10, Rituxan and MabThera in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety between CT-P10,
      Rituxan and MabThera in Patients with Rheumatoid Arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>over the first 24 weeks</time_frame>
    <description>AUC0 last: area under the serum concentration-time curve covering both infusions, time to the last measurable concentration
AUC0-∞: area under the serum concentration-time curve covering both infusion, time zero to infinity
Cmax: maximum concentration after the second infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy parameter</measure>
    <time_frame>at Week 24</time_frame>
    <description>The change from Baseline in disease activity measured by DAS28 (CRP) at Week 24
DAS28, Hybrid ACR, Joint damage</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">384</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>CT-P10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rituximab, CT-P10(experimental drug), 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituxan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MabThera</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT-P10</intervention_name>
    <description>1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion</description>
    <arm_group_label>Rituxan</arm_group_label>
    <arm_group_label>MabThera</arm_group_label>
    <other_name>MabThera</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituxan</intervention_name>
    <description>1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion</description>
    <arm_group_label>CT-P10</arm_group_label>
    <arm_group_label>MabThera</arm_group_label>
    <other_name>rituximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MabThera</intervention_name>
    <description>1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion</description>
    <arm_group_label>CT-P10</arm_group_label>
    <arm_group_label>Rituxan</arm_group_label>
    <other_name>rituximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is male or female between 18 and 75 years old, inclusive.

          2. Patient has a diagnosis of RA according to the revised 1987 ACR classification
             criteria (Arnett et al 1988) for at least 6 months prior to randomization.

          3. Patient has active disease as defined by the presence of 6 or more swollen joints (of
             66 assessed) and 6 or more tender joints (of 68 assessed), and serum CRP ≥1.5 mg/dL
             (≥15 mg/L) or an ESR ≥28 mm/hour.

          4. Patient has experienced an inadequate response to previous or current treatment with
             the anti-TNF agents infliximab

          5. Patient has a proper discontinuation period after treatment with interleukin-1
             receptor (IL-1R) antagonist, interleukin-6 receptor (IL-6R) antibody, or abatacept.

        Exclusion Criteria:

          1. Patient has taken more than 2 biologic agents.

          2. Patient has previously been administered Rituximab or participated in a Rituximab
             biosimilar study.

          3. Patient has allergies or hypersensitivity to murine, chimeric, human, or humanized
             proteins.

          4. Patient has current or past history of chronic infection with hepatitis B, hepatitis
             C, or infection with human immunodeficiency virus (HIV)-1 or -2 or who has a positive
             result to the screening test for these infections.

          5. Patient has an infection requiring oral antibiotics 2 weeks before randomization,
             parenteral injection of antibiotics 4 weeks before randomization, other serious
             infection 6 months before randomization, a history of recurrent herpes zoster or other
             chronic or recurrent infection 6 weeks before randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DaeHyun Yoo, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheuma Zentrum Favoriten GmbH</name>
      <address>
        <city>Wien</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <link>
    <url>http://www.celltrion.com/</url>
    <description>Homepage of CELLTRION</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2014</study_first_posted>
  <disposition_first_submitted>May 30, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>May 30, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 15, 2017</disposition_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

